Celyad bounces back from heart study flop to ink a $312M I/O deal with Ono
Just a few days after its stem cell therapy for damaged hearts flunked a mid-stage study, Belgium’s Celyad is back with a Japanese pharma deal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
